314 related articles for article (PubMed ID: 11222392)
1. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
[TBL] [Abstract][Full Text] [Related]
2. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
3. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo.
Jiang X; Ng E; Yip C; Eisterer W; Chalandon Y; Stuible M; Eaves A; Eaves CJ
Blood; 2002 Nov; 100(10):3731-40. PubMed ID: 12393460
[TBL] [Abstract][Full Text] [Related]
4. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
[TBL] [Abstract][Full Text] [Related]
5. Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3.
Tomasson MH; Williams IR; Li S; Kutok J; Cain D; Gillessen S; Dranoff G; Van Etten RA; Gilliland DG
Blood; 2001 Mar; 97(5):1435-41. PubMed ID: 11222391
[TBL] [Abstract][Full Text] [Related]
6. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Skórski T; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
[TBL] [Abstract][Full Text] [Related]
7. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
Zhang X; Wong R; Hao SX; Pear WS; Ren R
Blood; 2001 Jan; 97(1):277-87. PubMed ID: 11133772
[TBL] [Abstract][Full Text] [Related]
8. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
9. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.
Wang Y; Cai D; Brendel C; Barett C; Erben P; Manley PW; Hochhaus A; Neubauer A; Burchert A
Blood; 2007 Mar; 109(5):2147-55. PubMed ID: 17090651
[TBL] [Abstract][Full Text] [Related]
10. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
[TBL] [Abstract][Full Text] [Related]
11. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.
Holyoake TL; Jiang X; Jorgensen HG; Graham S; Alcorn MJ; Laird C; Eaves AC; Eaves CJ
Blood; 2001 Feb; 97(3):720-8. PubMed ID: 11157490
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition.
Donato NJ; Wu JY; Zhang L; Kantarjian H; Talpaz M
Blood; 2001 May; 97(9):2846-53. PubMed ID: 11313280
[TBL] [Abstract][Full Text] [Related]
13. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
Million RP; Aster J; Gilliland DG; Van Etten RA
Blood; 2002 Jun; 99(12):4568-77. PubMed ID: 12036890
[TBL] [Abstract][Full Text] [Related]
14. The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
Gustafsson K; Jamalpour M; Trinh C; Kharas MG; Welsh M
J Hematol Oncol; 2014 Jun; 7():45. PubMed ID: 24952416
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine phosphorylation of proteins in primary human myeloid leukemia cells stimulated by cytokines: analysis of the frequency of phosphorylation, and partial identification and semi-quantification of signaling molecules.
Hagiwara S; Iki S; Urabe A; Saeki K; Miwa A; Togawa A; Ozawa K; Takaku F; Yuo A
Int J Hematol; 1998 Dec; 68(4):387-401. PubMed ID: 9885438
[TBL] [Abstract][Full Text] [Related]
16. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
Hao SX; Ren R
Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
[TBL] [Abstract][Full Text] [Related]
17. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
Estrov Z; Talpaz M; Zipf TF; Kantarjian HM; Ku S; Ouspenskaia MV; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
J Cell Physiol; 1996 Mar; 166(3):618-30. PubMed ID: 8600166
[TBL] [Abstract][Full Text] [Related]
18. Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression.
Wetzler M; Kurzrock R; Lowe DG; Kantarjian H; Gutterman JU; Talpaz M
Blood; 1991 Nov; 78(9):2400-6. PubMed ID: 1932751
[TBL] [Abstract][Full Text] [Related]
19. Suppression of chronic myelogenous leukemia colony growth by interleukin-4.
Estrov Z; Markowitz AB; Kurzrock R; Wetzler M; Kantarjian HM; Ferrajoli A; Gutterman JU; Talpaz M
Leukemia; 1993 Feb; 7(2):214-20. PubMed ID: 8426475
[TBL] [Abstract][Full Text] [Related]
20. New models to investigate mechanisms of disease genesis from primitive BCR-ABL(+) hematopoietic cells.
Eaves C; Jiang X; Eisterer W; Chalandon Y; Porada G; Zanjani E; Eaves A
Ann N Y Acad Sci; 2003 May; 996():1-9. PubMed ID: 12799276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
